ALZHEIMER'S DEMENTIA
Dementia is a
clinical syndrom characterised with acquired deterioration of cognitive
functioning and emotional capacities, which impaires everyday activity and
quality of life. The dementias can be categorized according to etiology,
neuropathology or clinical presentation. Four major groups of dementias have
been defined: Alzheimer’s dementia (AD); the Parkinson’s group (including Lewy
Body disease, dementia of Parkinson’s and Alzheimer’s dementia with
Parkinson’s); the frontotemporal group (including Pick’s disease and Semantic
dementia); and the vascular group (including large and small vessel disease1.
This review focuses on the Alzheimer's dementia, named after german doctor
Alois Alzheimer who, in 1906, found changes in the brain (amyloid plaques and
neurofibrillary tangles) of a woman who died, for that time, of an unknown
mental disease.
Epidemiology
AD is the most common type of dementia in clinical and
autopsy surveys1. AD is a neurodegenerative disorder that is
estimated to affect 15 million people around the world2. It is
estimated that by 2050 the number of patients with AD could be as high as 25
million3. The current
prevalence of AD in the U.S. is estimated at 4.5 million, a number expected to
rise threefold over the next 50 years as the population ages4.
Etiology/Risk factors
Cerebral degeneration, with selective neuronal death
induced by extracellular amyloid deposits in the form of senile plaques and
intracellular neurofibrillary tangles composed of helical paired tau protein,
is the best-studied pathological event related to AD. Neurofibrillary tangles
are composed of an abnormally hyperphosphorylated intracellular protein called
tau, tightly wound into paired helical filaments and thought to impact
microtubule assembly and protein trafficking, resulting in the eventual demise
of neuronal viability. The extracellular amyloid plaque deposits are composed
of a proteinacious core of insoluble aggregated amyloid-β (Aβ) peptide and have
led to the foundation of the amyloid hypothesis5. In AD, multiple
regions of brain gray matter have a profound neuronal loss, including basal
forebrain, hippocampus, entorhinal, and temporal cortices. Braak and Braak
suggest that the neurodegenerative process begins with neuronal loss in the
glutamatergic pathways of the entorhinal cortex before extending to the
hippocampus and amygdala and then more widely to neocortical and subcortical
areas6.
The amyloid cascade hypothesis is one of the theories
of pathogenesis for Alzheimer disease7. The most important
abnormality is an excess of Aβ peptides brought about through either
overproduction or failiure in degredation. It seems that late-life onset AD
results from a failure of metabolism and degradation of Aβ, while mutations in
the “Alzheimer genes” (Presenilin I, Presenilin II, and APP) leeds to
overproduction of Aβ. Previously, it was considered that the plaque was
necessary to initiate this toxic cascade, but it is now considered more likely
that the Aβ monomers and oligomers initiate the process, long before organizing
into plaques.
Secondary protective responses such as microglial
activation, an inflammatory response and free radical formation are part of the
toxic cascade induced by amyloid accumulation, which ultimately contributes to
neuronal death, leading to the clinical manifestations of dementia1.
Beside mutations in APP, PS1 and PS2 genes molecular
genetic studies have found that polymorphisms in APOE gene are implicated in AD
pathogenesis8. APOE has critical functions in redistributing lipids
among CNS cells for normal lipid homeostasis, repairing injured neurons,
maintaining synapto-dendritic connections, and scavenging toxins. In
Alzheimer's disease, apoE acts directly or in concert with age, head injury,
oxidative stress, ischemia, inflammation, and excess amyloid beta peptide
production to cause neurological disorders, accelerating progression, altering
prognosis, or lowering age of onset9.
Recent studies show that these proteins are also
involved in several neuroplasticity-signaling pathways (NMDA-PKA-CREB-BDNF,
reelin, wingless, notch, among others). DNA damage caused by oxidative stress
is not completely repaired in neurons and is accumulated in the genes of
synaptic proteins. Several functional single-nucleotide
polymorphisms (SNPs) in synaptic genes may be interesting candidates to
explore in AD. Thus, experimental evidence shows that proteins implicated in AD
pathogenesis have differential roles in several signaling pathways related to
neuromodulation and neurotransmission in adult and developing brain. It has
been suggested that oxidative stress effects on DNA and inherited variations in
synaptic genes may explain in part the synaptic dysfunction seen in AD8.
Earlier investigations have shown that permanent
activation of glial cells in the brains of AD patients promotes the production
of excessive quantities of free radicals, nitric oxide, and cytokines, which
could be detrimental to neuronal cells. Damage to the blood-brain barrier by
inflammatory processes results in the influx of peripheral immune system cells
and local immune reactions10.
Glutamatergic dysfunction plays an important role in
the pathogenesis of this illness, although this disturbance is probably a
secondary phenomenon to other neurochemical, genetic or metabolic changes, essential
to the development of AD11.
Of approximately 200 peptides that are known to exist
in the body, 80 carry out functions as neurotransmitters and about 20 have been
linked to AD. The most notable points in AD could be the reduction in substance
P in the cerebral cortex, hippocampus, basal ganglia and cephalospinal fluid;
the diminished levels of somatostatin in the same structures except for the
basal ganglia; the reduction in the amount of vasopressin except in the
temporal lobe; and the increased levels of dynorphin and leucine enkephalin12.
Regarding risk factors, age is the strongest risk
factor for AD. Gender13, marital status14 and living in
an urban area have been suggested as possible risk factors for AD15.
Lower education has repeatedly been identified as a risk factor for the
development of AD, while higher education correlates with older age at onset
and possibly with lower overall risk16. This pattern has been
attributed to brain and cognitive reserve. Hypertension may impair cognitive
functions and is related to the occurrence of not only vascular dementia but
also AD, while the relationship between cholesterol and dementia varies,
depending on when the cholesterol is measured over the life course - midlife
high cholesterol level appears to be a risk factor for dementia, especially AD17.
There is also evidence for an elevated risk of both vascular dementia and AD in
patients with type 2 diabetes mellitus, albeit with strong interaction of other
factors such as hypertension, dyslipidaemia and ApoE genotype18. Population-based
studies have shown that those with type 2 diabetes mellitus have an increased
risk of cognitive impairment, dementia, and neurodegeneration. There are many
mechanisms through which diabetes could increase risk of dementia, including
glycemia, insulin resistance, oxidative stress, advanced glycation endproducts,
inflammatory cytokines, and microvascular and macrovascular disease19.
Investigations have targeted three so-called
“Alzheimer genes,” Presenilin I, Presenilin II, and APP, which are thought to work
through increased production of Aβ peptides and are held responsible for many
familial cases of AD. These genes are accounting for around 5% of cases,
usually the early-onset variant. Most AD cases, particularly with onset after
the age of 65, occur in the absence of one of the causative genes and without
an identified family history. The major susceptibility gene associated with
late-onset AD cases is apolipoprotein e4 (APOe4). By age 85 those homozygous
for the APOe4 allele (2% of the population) have a 50 – 90% chance of
developing AD, and those heterozygous for the APOe4 allele (15% of the
population) have a 45% chance, in contrast to the 20% chance in the general
population20, 21.
Although the APOe4 allele is the only proven genetic
risk factor for the late form of the disease, genetic epidemiological studies
suggest that other loci are also involved22.
It is improtant to stress the role of lifestyle in
development of AD. Patients with varied activities, including intellectual,
physical, recreational and social activities, are less likely to develop AD23.
Also, social network size seems to play a role in preserving cognitive
functioning24.
The diagnosis of AD is primarily based on symptoms and
signs, according to DSM-IV-TR and ICD-10 diagnostic criteria. Memory impairment
is clinically most signifficant. The presence of characteristic symptoms such
as problems with retaining recent information or problems to come up with words
are suggestive of AD. Language, praxis and recognition skills, are affected
even early in the presentation, while motor and sensory symptoms are absent
until late in the course of the disease. AD has a gradual and progressive
course, typically 10 years from diagnosis to death. The cholinesterase
inhibitors have had some effect on the course of disease for individual
subjects, though population trends have been harder to demonstrate25.
Assesment of cognitive functioning is necessary for
making initial diagnose of dementia. For this reason, mesauring scales are used
in patients with dementia for assesment of cognitive functioning,
psychopathology and psychosocial functioning.
The most
commonly used instrument for assesment of cognitive deterioration is Mini
Mental state Examination (MMSE). It takes 5-10 minutes to complete the MMSE,
and maximum result is 30 points. In many countries MMSE has become a part of
routine practice26. Alzheimer disease assessment scale (ADAS) also
measures cognitive functioning, memory, concentration, mood, behavioral
disturbances27. It is consisted of 21 items. The time to complete
ADAS is around 45 minutes. Severe impairement battery (SIB) is used to asses
cognitive functioning in patients with severe AD, while Multidimensional
observation scale for elderly subjects (MOSES) is used to asses cognitive and
psychosocial functioning28. Cohen-Mansfield Agitation Inventory
(CMAI) is used for assesment of manifestation and frequency of agitation in
patients with dementia. Neuropsychiatric inventory (NPI) is a scale used for
assesment of psychopathology in patients with dementia29.
Treatment
Tacrine was
the first cholinesterase inhibitor approved by the Food and Drug Administration
(FDA) for the symptomatic treatment of AD but was subsequently withdrawn from
the market place due to hepatotoxicity, resulting in an unacceptable risk
benefit profile for the drug5. Other cholinesterase inhibitors -
donepezil, rivastigmine and galantamine have better safety and tolerability
profiles, and are considered to be the first line pharmacotherapy for mild to
moderate Alzheimer's disease. These drugs have slightly different
pharmacological properties, but they all work by inhibiting the breakdown of
acetylcholine by blocking the enzyme acetylcholinesterase. Donepezil and
galantamine are both selective acetylcholinesterase inhibitors30,31,
whereas rivastigmine is an inhibitor of both acetylcholinesterase and
butyrylcholinesterase32. The
most that these drugs could achieve is to modify the manifestations of
Alzheimer's disease33.
In 2003, memantine, an Nmethyl-D-aspartate (NMDA)
antagonist, was approved for the treatment of moderate severity AD. Memantine,
a moderate-affinity, voltage-dependent, uncompetitive antagonist of NMDA
receptor, shows neuroprotective effects in patients with moderate-to-severe AD.
Memantine is a drug with neuroprotective and cognition-enhanced properties,
which can be combined with other treatments for AD. Thus, memantine does not
stop or reverse AD, but its moderating effect in protecting the brain from the
toxic levels of calcium, allows normal signaling among brain neurons34.
Oxidative stress and glutamate induced excitotoxicity are thought to play a
critical role in the neurodegenerative process of AD35,36. With
advancing age, neurons encounter increased oxidative stress and impaired energy
metabolism, which compromise the function of proteins that control membrane
excitability and subcellular Ca(2+) dynamics. Toxic forms of amyloid
beta-peptide can induce Ca(2+) influx into neurons by inducing
membrane-associated oxidative stress or by forming an oligomeric pore in the
membrane, thereby rendering neurons vulnerable to excitotoxicity and apoptosis37.
Although the precise molecular mechanism of beta-amyloid protein neurotoxicity
remains elusive, our and other numerous findings have demonstrated that beta-amyloid
protein directly incorporated into neuronal membranes formed calcium-permeable
ion channels (amyloid channels) and resulted in an abnormal elevation of the
intracellular calcium levels38.
Blockade of the NMDA receptor, one of the principal
excitatory glutamate receptors in the brain, has been shown to have
neuroprotective effects in a number of acute preclinical in vitro and in
vivo models39.
The mechanism of action of some new investigated
compunds include interfering with Aβ aggregation, enhancing its metabolism,
diminishing the production of toxic Aβ peptides and enhancing the enzymatic
formation of non-soluble Aβ peptides.
One of the therapeutic targets is the Aβ itself. A
number of strategies to reduce soluble Aβ are currently being employed both
preclinically as well as clinically, and include antibody based approaches, and
reagents that disrupt the structure of Aβ, such as metal chelators40.
Two β-secretase genes have been identified in humans, referred to as
BACE-1 and BACE-2, colocalized with APP in the endosomal compartment. Only
BACE-1 is significantly expressed in brain, particularly in neurons. Inhibition
of β-secretase is one of a promising strategy for treamtent of AD, and specific
BACE-1 inhibitors should have therapeutic potential to slow or halt the
progression of this disease5.
Depressive
symptoms are present in two thirds of patients with dementia. It is necessary
to apply antidepressants in those cases. Selective serotonine reuptake inhibitors (SSRI's) are the first
treatment choice. Tricyclic antidepressants (TCA's) should be used cautiously.
Nortriptylin has better tolerance in comparison to other TCA's. On the other
hand, amoxapine should be avoided because of potential of causing
extrapyramidal side effects (EPS). Monoaminooxidaze inhibitors should also be
used cutiously because of their potential of causing orthostatic hypotension,
and also because their application requires special diet which can be a
limitiation to difficult for some patients41,42.
In a recent investigation that studied proton
magnetic resonance spectroscopy (1H-MRS) changes in early to intermediate (3-6
weeks) responders to antidepressant treatment with selective serotonin reuptake
inhibitors, authors concluded that significant increase
in choline to creatine ratio from the first to the second spectroscopic scan
during the antidepressant treatment, compared to almost identical values of N-acetyl-aspartate (NAA) to creatine ratio, suggested increased
turnover of cell membranes as a mechanism of the early response to the
antidepressant drug therapy.(43)
Antipsychotics are indicated in cases of psychotic symptoms in
demented patients. Antipsychotics with high potency more often induce akathisia
and parkinsonism in elderly population, while antipsychotics with low potency
more often cause sedation, confusion, delirium and ortostatic hypotension,
along with periferal anticholinergic side effects. Atypical antipsychotics are
the preferred treatment for symptoms such as delusions, hallucinations,
agitation and aggressive behaviour. The most widely used are olanzapine and
risperidone43.
Benzodiazepines are used in the treatment of anxiety and agitation, primarily lorazepam and oxazepam because of
lack of active metabolites and because these medications do not metabolize in
liver. Side effects of such treatment include sedation, worsening in cognitive
functioning, delirium and higher risk of falling. Anticonvulsive medications are used as mood stabilizers in
non-psychotic patients with behavioral disorders41,42.
Elderly population is more sensitive to
pharmacotherapy, as a result of changes in pharmacodynamics (changes in number
of neurons, changes of receptors) and pharmacokinetics (changes in absorption,
distribution, metabolism, excretion nad protein binding). Bearing this in mind,
the lowest effective doses of psychopharmacs are to be used, following the
general rule «start low, go slow», avoiding side effects as much as possible.
It is necessary to recognize potential reasons for not taking therapy, such as
living alone, impaired sight and/or hearing, and cognitive deterioration. Also,
it is necessary to consider possibility of interactions between psychopharmacs
and other medications, especially considering changes in pharmacodynamics and
pharmacokinetics. It is assumed that in the future treatment efficacy will be
monitored in vivo through amyloid imaging and serum/CSF biomarkers.
Many preventive approaches to AD have been identified,
but no randomized controlled trials (RCTs)
support their efficacy. Evidence from RCTs supports the effectiveness of blood
pressure control in reducing incidence of AD, but demonstrates that
postmenopausal women's use of estrogen is ineffective in reducing it.
Observational studies suggest that some preventive approaches, such as healthy
lifestyle, ongoing education, regular physical activity, and cholesterol
control, play a role in prevention of AD. These approaches can and should be used
for every patient because they carry no significant risk. Currently, no
effective pharmacologic interventions have been researched enough to support
their use in prevention of AD44.
Health professionals should educate patients,
especially patients at higher risk of AD, about preventive strategies and
potentially modifiable risk factors.
I am 29 years old and have been diagnosed with breast cancer, ease of treatment and a similar story, except for my first acceptance as a rejection of herbal medicine. I was not part of the Perseid movement and did not really build relationships with any of them, I just believed in their operation. I say this because it was during the use of Dr. Itua herbal medicine that I now attest that herbal medicine is real, the phytotherapy Dr. Itua heal my breast cancer which I suffered for 2 years. Dr. Itua herbal medicine is made of natural herbs, with no side effects, and easy to drink. If you have the same breast cancer or any type of human illness, including HIV / AIDS, herpes cancer,Ovarian Cancer,Pancratics cancers, bladder cancer, bladder cancer, prostate cancer, Glaucoma., Cataracts,Macular degeneration,Cardiovascular disease,Lung disease.Enlarged prostate,Osteoporosis.Alzheimer's disease,
ReplyDeleteDementia.kidney cancer, lung cancer, skin cancer, skin cancer and skin cancer.testicular Cancer, , LEUKEMIA, VIRUSES, HEPATITIS, INFERTILITY WOMEN / MAN, LOT OF LOVE, LOTTERY. ITS CONTACT EMAIL / WHATSAPP: info@drituaherbalcenter.com Or drituaherbalcenter@gmail.com/ +2348149277967